ArchiveSeptember 2014

Stem cell trials are here

Human Placenta-Derived Cells (PDA-001) for the Treatment of Adults With Multiple Sclerosis: A Randomized, Placebo-Controlled, Multiple-Dose Study Fred D. Lublin, James D. Bowen, John Huddlestone, Marcelo Kremenchutzky, Adam Carpenter, John R. Corboy, Mark S. Freedman, Lauren Krupp, Corri Paulo, Robert J. Hariri, Steven A. Fischkoff DOI: Background:Infusion of PDA-001, a preparation of...

Another pro-myelinating factor

 Cruz-Martinez P, Martinez-Ferre A, Jaramillo-Merchán J, Estirado A, Martinez S, Jones J.FGF8 Activates Proliferation and Migration in Mouse Post-Natal Oligodendrocyte Progenitor Cells. PLoS One. 2014 Sep;9(9):e108241. doi: 10.1371/journal.pone.0108241. eCollection 2014 Fibroblast growth factor 8 (FGF8) is a key molecular signal that is necessary for early embryonic development of the...

ClinicSpeak: switching from injectables to fingolimod

Satisfaction is high in those who switch from injectables to fingolimod: #ClinicSpeak #MSBlog #MSResearch “This open-label study below shows that MSers switching from injectables therapies (IFNbeta and GA) do better on fingolimod a second-line DMT in most of Europe. This study mirrors our clinical experience with the drug. Are you surprised MSers do better when moving to an oral therapy...

How much does a Relapse Cost?

K. O׳Connell K et al. Economic costs associated with an MS relapse Mult Scler Rel DisordDOI: 10.1016/j.msard.2014.09.002 Background:Multiple sclerosis (MS) commonly affects young adults and can be associated with significant disability resulting in considerable socioeconomic burden for both patient and society.Aims:The aim was to determine the direct and indirect cost of an MS relapse...

Fampridine making facial pain worse?

Birnbaum G, Iverson J. Dalfampridine may activate latent trigeminal neuralgia in patients with multiple sclerosis. Neurology. 2014 Sep. pii: 10.1212/WNL.0000000000000931. [Epub ahead of print]  OBJECTIVE: To determine the effect of dalfampridine (4-aminopyridine), a broad-spectrum, voltage-dependent potassium channel blocker, on patients with trigeminal nerve dysfunction due to multiple...

IL-17 increases in secondary progressive MS

Huber AK, Wang L, Han P, Zhang X, Ekholm S, Srinivasan A, Irani DN, Segal BM. Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS. Neurology. 2014 . pii: 10.1212/WNL.0000000000000908. [Epub ahead of print] OBJECTIVE:In the current exploratory study, we longitudinally measured immune parameters in the blood of individuals with relapsing-remitting multiple...

Biomarker for transition to progression

Are the relapsing and progressive phases of MS truly different from each other? #MSResearch #MSBlog “The following study uses a novel approach to differentiate MSers with different clinical forms of the disease, i.e. RRMS vs. SPMS vs. PPMS. The use a technique that profiles the metabolism of MSers and find that the metabolic profiles are different between the clinical sub-types. This...

RULES OF ENGAGEMENT

One poster asked what are the Rules of Engagement and how to post. What are the do’s and importantly don’ts of posting a comment. Many moons ago you will remember that you could post at will, you would post and it would appear. There could be some heated discussions.  However, invariably posts particularly on CCSVI would attract destructive Trolls…leading to all comments...

ClinicSpeak: second opinions in the NHS

You don’t have a legal right to a second opinion under the NHS. #ClinicSpeak #MSBlog #MSResearch “Somebody asked my advice at the Imperial Research Day yesterday about how to get a second opinion when their GP refuses. I told you that all NHS patients had a right to second opinion as enshrined in the NHS patient Charter. Apologies, I gave you incorrect information. The NHS Patient...

Imperial College MS Study Day 2014

How to treat MS in 2014: treat-2-target and prevent end-organ damage. #MSBlog #MSResearch “As promised the following is my presentation from yesterday at the Imperial College MS Study Day. My  talk generated a lot of questions about the new treatment paradigm of treating-2-target and preventing end-organ damage in MS. It will be interesting to see of the wider MS community adopt this...

Translate

Categories

Recent Posts

Recent Comments

Archives